Urinary 6-keto-PGF1 alpha after captopril and indomethacin: possible contribution of PGI2 to the antihypertensive mechanism of ACE inhibitors.
Minuz
P
P
Degan
M
M
Covi
G
G
Lechi
C
C
Velo
G P
GP
Lechi
A
A
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine*; D000328:Adult; D000450:Aldosterone / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril / Q000627:therapeutic use*; D011464:Epoprostenol / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007213:Indomethacin / Q000627:therapeutic use*; D007610:Kallikreins / Q000652:urine; D008875:Middle Aged; D011392:Proline / Q000031:analogs & derivatives*; D012083:Renin / Q000097:blood
D000806:Angiotensin-Converting Enzyme Inhibitors; D000450:Aldosterone; D015121:6-Ketoprostaglandin F1 alpha; D011392:Proline; D002216:Captopril; D011464:Epoprostenol; D007610:Kallikreins; D012083:Renin; D007213:Indomethacin